Glenmark’s Ryaltris Close To Entry In Major Eastern Europe Market
Indian Firm Has Launched Already In Ukraine, Australia And South Africa
Executive Summary
Having divested a basket of allergy treatments in Russia and the CIS to Dr Reddy’s last year, Glenmark is gearing up to launch its novel Ryaltris nasal spray in a major Eastern Europe market.
You may also be interested in...
Glenmark Partners With Menarini On Ryaltris
Glenmark has struck a marketing deal with Menarini to commercialize the Indian firm’s Ryaltris nasal spray in 33 countries across Europe. The agreement adds to a network of licenses already in place across the world.
Dr Reddy's Adds To OTC Portfolio With Glenmark Deal
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Pegfilgrastim Next As Fresenius Kabi Eyes Five Biosimilars In 2025
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: